RedHill’s RHB-102 Targets Major GLP-1 Market Challenge: Phase 2 Study Planned for GI Side Effects
Market Chameleon (Mon, 5-Jan 5:33 AM ET)
PRNewswire (Mon, 5-Jan 7:00 AM ET)
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
PRNewswire (Mon, 15-Dec 7:00 AM ET)
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
PRNewswire (Mon, 1-Dec 7:00 AM ET)
Market Chameleon (Wed, 5-Nov 5:38 AM ET)
RDHL Strikes $4 Million Partnership to Accelerate Talicia Sales and Bolster Nasdaq Compliance
Market Chameleon (Mon, 20-Oct 5:53 AM ET)
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
Redhill Biopharma Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol RDHL.
As of February 11, 2026, RDHL stock price declined to $0.97 with 13,244 million shares trading.
RDHL has a beta of 2.84, meaning it tends to be more sensitive to market movements. RDHL has a correlation of 0.27 to the broad based SPY ETF.
RDHL has a market cap of $4.96 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, RDHL traded as high as $12.50 and as low as $.26.
RDHL has underperformed the market in the last year with a price return of -82.6% while the SPY ETF gained +15.7%. RDHL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -9.3% and -27.1%, respectively, while the SPY returned +1.9% and -0.5%, respectively.
RDHL support price is $.95 and resistance is $1.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RDHL shares will trade within this expected range on the day.